Zoetis Inc. (ZTS) Net Profit Margin: 27.79%
Is Zoetis Inc.’s net profit margin high or low?
Zoetis Inc.'s net profit margin of 27.79% is in line with its 5-year average of 26.57%, near the high end of its 5-year range (24.54%–28.23%).
The net profit margin for Zoetis Inc. (ZTS) is 27.79% as of Wednesday, June 10, 2026. It is above its 12-month average by 0.89% (27.55%).
ZTS Net Profit Margin Chart
ZTS Average Net Profit Margin Chart
ZTS Current vs Average Net Profit Margin Chart
ZTS Net Profit Margin Metrics
NET PROFIT MARGIN
27.79%
NET PROFIT MARGIN AVG TTM
27.55%
NET PROFIT MARGIN AVG 3Y
27.17%
NET PROFIT MARGIN AVG 5Y
26.57%
NET PROFIT MARGIN AVG 10Y
22.55%
NET PROFIT MARGIN AVG 15Y
18.14%
NET PROFIT MARGIN AVG 20Y
16.86%
CURRENT VS TTM AVG
+0.89%
CURRENT VS 3Y AVG
+2.28%
CURRENT VS 5Y AVG
+4.59%
CURRENT VS 10Y AVG
+23.22%
CURRENT VS 15Y AVG
+53.20%
CURRENT VS 20Y AVG
+64.83%
ZTS Competitors' Net Profit Margin
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Zoetis Inc. (ZTS) | $34.20B | 27.79% | 27.55% | 27.17% | 26.57% |
| Centene Corporation (CNC) | $31.94B | -3.25% | -0.70% | 0.29% | 0.65% |
| Agilent Technologies, Inc. (A) | $37.17B | 19.55% | 19.27% | 18.75% | 17.94% |
| Medline Inc. (MDLN) | $30.90B | 3.31% | 4.39% | 2.42% | 2.42% |
| IQVIA Holdings Inc. (IQV) | $30.60B | 8.33% | 8.63% | 8.47% | 7.22% |
| DexCom, Inc. (DXCM) | $29.24B | 19.31% | 16.12% | 14.73% | 15.57% |
| Biogen Inc. (BIIB) | $29.00B | 13.92% | 15.03% | 17.95% | 19.29% |
| Veeva Systems Inc. (VEEV) | $26.73B | 28.37% | 27.22% | 24.83% | 24.72% |
| Humana Inc. (HUM) | $43.78B | 0.82% | 0.97% | 1.82% | 2.53% |
| IDEXX Laboratories, Inc. (IDXX) | $44.47B | 24.63% | 23.70% | 22.66% | 22.55% |
Margin Comparison
Operating Margin
37.6%
Net Profit Margin
27.8%
Zoetis Inc. Net Profit Margin Formula & Definition
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Zoetis Inc. Net Profit Margin FAQ
- What is the net profit margin for Zoetis Inc. (ZTS)?
- The net profit margin for ZTS stock is 27.79%.
- Is Zoetis Inc.'s net profit margin high or low?
- Zoetis Inc.'s net profit margin of 27.79% is in line with its 5-year average of 26.57%, near the high end of its 5-year range (24.54%–28.23%).
- What is the TTM average net profit margin for Zoetis Inc. (ZTS)?
- The TTM average net profit margin for ZTS stock is 27.55%.
- What is the 3Y average net profit margin for Zoetis Inc. (ZTS)?
- The 3Y average net profit margin for ZTS stock is 27.17%.
- What is the 5Y average net profit margin for Zoetis Inc. (ZTS)?
- The 5Y average net profit margin for ZTS stock is 26.57%.
- What is the 10Y average net profit margin for Zoetis Inc. (ZTS)?
- The 10Y average net profit margin for ZTS stock is 22.55%.
- What is the 15Y average net profit margin for Zoetis Inc. (ZTS)?
- The 15Y average net profit margin for ZTS stock is 18.14%.
- What is the 20Y average net profit margin for Zoetis Inc. (ZTS)?
- The 20Y average net profit margin for ZTS stock is 16.86%.
Zoetis Inc. Net Profit Margin History
| DATE | NET PROFIT MARGIN |
|---|---|
| 2025-12-31 | 28.23% |
| 2024-12-31 | 26.86% |
| 2023-12-31 | 27.43% |
| 2022-12-31 | 26.16% |
| 2021-12-31 | 26.20% |
| 2020-12-31 | 24.54% |
| 2019-12-31 | 23.96% |
| 2018-12-31 | 24.52% |
| 2017-12-31 | 16.28% |
| 2016-12-31 | 16.80% |
| 2015-12-31 | 7.11% |
| 2014-12-31 | 12.18% |
| 2013-12-31 | 11.05% |
| 2012-12-31 | 10.06% |
| 2011-12-31 | 5.79% |
| 2010-12-31 | 3.07% |
| 2009-12-31 | -3.62% |
Related Metrics
About Zoetis Inc.
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Kristin C. Peck